Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59858 | 0.87 | TGM2 (0.55) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL12479404 | 0.84 | P2RX7 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2CASR | |
| SCHEMBL3176740 | 0.83 | HIF1A (0.56) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL410698 | 0.81 | TSHR (0.52) | ALDH1A1KMT2A | |
| SCHEMBL2449430 | 0.81 | TGM2 (0.53) | NPC1RAB9AALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL23805061 | 0.80 | NPC1 (0.72) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL8766316 | 0.80 | HPGD (0.48) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL30858769 | 0.80 | NPC1 (1.00) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL5082541 | 0.79 | KMT2A (0.67) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL15938100 | 0.79 | ALDH1A1 (0.49) | NPC1RAB9AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| CN-110785426-A | Compositions and methods for modulating PPP2R1A | 加利福尼亚大学董事会 | 2020-02-11 | — | — | CN | disclosed |
| CN-110461322-A | For inhibiting the composition and method of plasma membrane protein 4 | UNIV CALIFORNIA | 2019-11-15 | — | — | CN | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| WO-2018144871-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144871-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144869-A1 | COMPOSITONS AND METHODS FOR MODULATING UBA5 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144869-A1 | COMPOSITONS AND METHODS FOR MODULATING UBA5 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-0505972-B1 | Process for producing styrenic copolymer | IDEMITSU KOSAN CO (JP) | 1997-06-11 | — | — | EP | disclosed |
| EP-0490269-B1 | Graft copolymer and process for producing the same | IDEMITSU KOSAN CO (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5250629-A | Graft polymerization of styrene and ethylenically unsaturated monomer using transition metal catalysts, organoaluminum compounds; films, packaging, automobile parts | IDEMITSU KOSAN CO., LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
| EP-0505972-A2 | Process for producing styrenic copolymer | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1992-09-30 | — | — | EP | disclosed |
| EP-0490269-A1 | Graft copolymer and process for producing the same | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | RTN4, RTN3, RCN1 | NPC1 2442/4885RAB9A 939/4885ALDH1A1 4014/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | NPC1 37/4885RAB9A 223/4885ALDH1A1 4188/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | NPC1 2966/4885RAB9A 2224/4885ALDH1A1 2969/4885 |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | PPP2R1A, PPP3CA, PPP2R2A | NPC1 3043/4885RAB9A 716/4885ALDH1A1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.